EVerZom, a Paris, France-based biopharmaceutical company specialized in the bioproduction of exosomes, raised €1.1m in funding.
Backers included institutional and private investors.
This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022.
Led by Jeanne Volatron, Co-founder and President, EVerZom is to develop an exosome bioproduction platform. Exosomes are biological nanoparticles released by cells as an intercellular communication system to transport biomolecules. They have the ability to deliver therapeutics or regenerate tissue in several pathologies, including osteoarthritis, heart failure, and liver and kidney diseases, conditions which impact more than 150 million patients worldwide.